657 related articles for article (PubMed ID: 18778390)
21. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
Fhima A; Henrion R; Lowenstein W; Charpak Y
Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
[TBL] [Abstract][Full Text] [Related]
22. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.
Nielsen S; Dietze P; Lee N; Dunlop A; Taylor D
Addiction; 2007 Apr; 102(4):616-22. PubMed ID: 17286641
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus.
Murphy DA; Belzer M; Durako SJ; Sarr M; Wilson CM; Muenz LR;
Arch Pediatr Adolesc Med; 2005 Aug; 159(8):764-70. PubMed ID: 16061785
[TBL] [Abstract][Full Text] [Related]
24. Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART).
Michel L; Giorgi R; Villes V; Poizot-Martin I; Dellamonica P; Spire B; Protopopescu C; Carrieri MP
Drug Alcohol Depend; 2009 Jan; 99(1-3):96-104. PubMed ID: 18774237
[TBL] [Abstract][Full Text] [Related]
25. HAART with didanosine once versus twice daily: adherence and efficacy.
Roca B; Lapuebla C; Vidal-Tegedor B
Int J Infect Dis; 2005 Jul; 9(4):195-200. PubMed ID: 15964537
[TBL] [Abstract][Full Text] [Related]
26. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004.
Donoghoe MC; Bollerup AR; Lazarus JV; Nielsen S; Matic S
Int J Drug Policy; 2007 Aug; 18(4):271-80. PubMed ID: 17689375
[TBL] [Abstract][Full Text] [Related]
27. The role of anger in adherence to highly active antiretroviral treatment in patients infected with HIV.
Leombruni P; Fassino S; Lavagnino L; Orofino G; Morosini P; Picardi A
Psychother Psychosom; 2009; 78(4):254-7. PubMed ID: 19468260
[TBL] [Abstract][Full Text] [Related]
28. One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients.
Park WB; Choe PG; Kim SH; Jo JH; Bang JH; Kim HB; Kim NJ; Oh M; Choe KW
J Intern Med; 2007 Mar; 261(3):268-75. PubMed ID: 17305649
[TBL] [Abstract][Full Text] [Related]
29. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.
Moatti JP; Carrieri MP; Spire B; Gastaut JA; Cassuto JP; Moreau J
AIDS; 2000 Jan; 14(2):151-5. PubMed ID: 10708285
[TBL] [Abstract][Full Text] [Related]
30. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.
Weber R; Huber M; Rickenbach M; Furrer H; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Ledergerber B;
HIV Med; 2009 Aug; 10(7):407-16. PubMed ID: 19490174
[TBL] [Abstract][Full Text] [Related]
31. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients.
Soyka M; Apelt SM; Lieb M; Wittchen HU
J Clin Psychopharmacol; 2006 Dec; 26(6):657-60. PubMed ID: 17110826
[TBL] [Abstract][Full Text] [Related]
32. HAART adherence strategies for methadone clients who are HIV-positive: a treatment manual for implementing contingency management and medication coaching.
Haug NA; Sorensen JL; Gruber VA; Lollo N; Roth G
Behav Modif; 2006 Nov; 30(6):752-81. PubMed ID: 17050764
[TBL] [Abstract][Full Text] [Related]
33. [Factors associated with adherence to therapy among HIV-infected patients in Bangui].
Mouala C; Kaba-Mebri J; Wata JB; Rey JL
Sante; 2006; 16(2):119-30. PubMed ID: 17116636
[TBL] [Abstract][Full Text] [Related]
34. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
[TBL] [Abstract][Full Text] [Related]
35. Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. The MANIF 2000 Study Group.
Reynaud-Maurupt C; Carrieri MP; Gastaud JA; Pradier C; Obadia Y; Moatti JP
AIDS Care; 2000 Aug; 12(4):461-70. PubMed ID: 11091779
[TBL] [Abstract][Full Text] [Related]
36. A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients.
Etard JF; Lanièce I; Fall MB; Cilote V; Blazejewski L; Diop K; Desclaux A; Ecochard R; Ndoye I; Delaporte E;
Trop Med Int Health; 2007 Oct; 12(10):1191-8. PubMed ID: 17956501
[TBL] [Abstract][Full Text] [Related]
37. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users.
Wood E; Kerr T; Zhang R; Guillemi S; Palepu A; Hogg RS; Montaner JS
HIV Med; 2008 Aug; 9(7):503-7. PubMed ID: 18484977
[TBL] [Abstract][Full Text] [Related]
38. Buprenorphine replacement therapy: a confirmed benefit.
Prescrire Int; 2006 Apr; 15(82):64-70. PubMed ID: 16604748
[TBL] [Abstract][Full Text] [Related]
39. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women.
Kapadia F; Vlahov D; Wu Y; Cohen MH; Greenblatt RM; Howard AA; Cook JA; Goparaju L; Golub E; Richardson J; Wilson TE
Am J Drug Alcohol Abuse; 2008; 34(2):161-70. PubMed ID: 18293232
[TBL] [Abstract][Full Text] [Related]
40. [Opioid substitution therapy in France: a physician's overview].
Michel L
Ann Pharm Fr; 2009 Sep; 67(5):369-73. PubMed ID: 19695374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
